|
"Currently, the new facility is undergoing CQV (commissioning, qualification, and validation) in preparation for cGMP manufacturing to begin in the fourth quarter of 2019. It is a multi-product facility designed to produce three different drug substances: allogeneic CAR T cells, messenger RNA (including formulations development) and adeno-associated viral vectors. Precision intends to initially use this new manufacturing center to create clinical trial material for its Phase I/II clinical trials in 2020. Precision BioSciences’ MCAT facility is designed to meet regulatory requirements in the United States, Europe and Japan."
Quelle #2
dazu diese Pipeline :
precisionbiosciences.com/pipeline/
"Mr. Buehler has over thirty years of experience in the healthcare industry. He spent the majority of his career with Alcon Laboratories, a publicly traded ophthalmology-focused healthcare company headquartered in Fort Worth, Texas. At Alcon, Mr. Buehler rose through the commercial organization, eventually becoming CEO, leading the company’s sale to Novartis and subsequently serving as Alcon division head within Novartis. He will assume the chairmanship of Precision’s Nominating and Corporate Governance Committee (replacing Mr. Kane), and will also join the company’s Audit Committee (replacing Dr. Adelman)."
CRSP Market Cap 2.94B CRISPR Therapeutics AG
DTIL Market Cap 453.90M Precision BioSciences, Inc.
NTLA Market Cap 669.96M Intellia Therapeutics, Inc.
EDIT Market Cap 1.16B Editas Medicine, Inc.
SRPT Market Cap 7.28B Sarepta Therapeutics, Inc.
...und uns Shareholder.
investor.precisionbiosciences.com/events/...data-presentation
"....The abstract outlining initial data from patients treated with PBCAR0191 at Dose Level 1 can be accessed on the ASH conference website. Data in the abstract include results as of the cutoff date of August 1, 2019 for three patients with advanced NHL treated at Dose Level 1. No significant toxicities were observed, including no serious adverse events and no dose-limiting toxicities. All patients had a minimum follow-up of 28 days (median 60 days). Two of the three patients experienced an objective tumor response by Lugano criteria, at day 14 and day 28, respectively. The third patient, who had previously progressed following treatment with axicabtagene ciloleucel (Yescarta®), an approved anti-CD19 autologous CAR T therapy, had not met the definition of response, but demonstrated evidence of central necrosis, decreased tumor size, and decreased PET-avidity at day 28, in the context of post-infusion tumor site pain and mild CRS symptoms. Peripheral blood analysis for CAR T cell expansion has identified preliminary evidence of cell expansion."
Ich bin eigentlich guter Dinge, habe aber auch schon oft daneben gelegen.
Viele Mitstreiter schein es ja hier nicht zu geben.
MfG
Kollaboration mit Lilly (DMD)
www.fiercebiotech.com/biotech/...henne-gene-therapy-135m-deal
endpts.com/...nome-editing-in-a-deal-worth-up-to-nearly-2-7b/
FDA akzeptiert den Zulassungsantrag für PBCAR19B
investor.precisionbiosciences.com/...ccepts-ind-pbcar19b-next
precisionbiosciences.com/pipeline/
Zahlen für 2020
"Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected
by mid-year 2021"
"Interim data releases expected from PBCAR269A and PBCAR20A in 2021 "
investor.precisionbiosciences.com/...uarter-and-fiscal-year-0
Precision BioSciences erwirbt die Rechte an CAR-T-Therapien von Servier zurück
investor.precisionbiosciences.com/...al-rights-its-allogeneic
Die zusätzlichen Daten aus der Phase 1 / 2a-Studie zu PBCAR0191, seinem handelsüblichen allogenen CAR T-Kandidaten gegen CD19 bei hämatologischen Malignitäten, zeigten, dass die Untersuchungstherapie weiterhin ein akzeptables Sicherheitsprofil
"Diese Ergebnisse bestätigen weiterhin die Aktivität von PBCAR0191 mit Strategien, die die Ablehnung mindern"
investor.precisionbiosciences.com/...ts-first-generation-cd19
allogener CAR-T Ansatz weist mangelnde Haltbarkeit auf
www.evaluate.com/vantage/articles/events/...lo-disappointment
Zahlen für Q3/21
investor.precisionbiosciences.com/...d-quarter-2021-financial
Zahlen für 2021
- to fund its operating expenses and capital expenditure requirements into mid-2023
- Progressing Ex Vivo Allogeneic CAR T Programs with Updates Expected in Mid-2022
investor.precisionbiosciences.com/...uarter-and-fiscal-year-1
Zahlen für Q1/22
- to fund its operating expenses and capital expenditure requirements into mid-2023
investor.precisionbiosciences.com/...t-quarter-2022-financial
Kollaboration mit Novartis + 50 Mio. $ Offering
investor.precisionbiosciences.com/...ne-editing-collaboration
investor.precisionbiosciences.com/...on-offering-common-stock
Das Offering ist eine Giftpille, wegen der 58% Verwässerung. Zu den existierenden 62 Mio. Aktien kommen nun nochmal 36 Mio. Stück dazu.
Zahlen für Q3/22
- Strong Cash Position Provides More than Two Years of Expected Runway
- our expected cash runway to the end of 2024
investor.precisionbiosciences.com/...d-quarter-2022-financial
Zahlen für Q4/22
- Cash Balance Provides Expected 2-Year Runway through Q1 2025
investor.precisionbiosciences.com/...uarter-and-fiscal-year-2
Zahlen für Q1/23
investor.precisionbiosciences.com/...t-quarter-2023-financial
Zahlen für Q2/23
- Cash Balance Provides Expected Runway Through Q1 2025
investor.precisionbiosciences.com/...d-quarter-2023-financial
"Als Gegenleistung für die weltweiten Rechte an Azer-Cel gegen Krebs sowie für die CAR T-Infrastruktur von Precision BioSciences und seine erfahrenen Zelltherapie-Teams erhält Precision eine
investor.precisionbiosciences.com/...egic-transaction-imugene
Steht alles drin
Mein konservativstes Kursziel für DTIL liegt bei 0,60$
Zahlen für Q3/23
- Precision to present late breaker PBGENE-HBV data at The Liver Meeting of AASLD in November 2023
- Extended cash runway through the end of 2025
investor.precisionbiosciences.com/...d-quarter-2023-financial
investor.precisionbiosciences.com/...nse-deal-tg-therapeutics
Interessant ist das die Vorabzahlung u.a. aus 7,5 Mio. $ Cash und einer Equitybeteilung von 2,92 Mio. Aktien je 0,77$ besteht
40 Mio. $ Offering
investor.precisionbiosciences.com/...-million-offering-common
Heftiger Verwässerung, Nach dem RS lag die Anzahl der Aktien bei ca. 4 Mio. Stück, nun nochmal 2,5 Mio. Stück obendrauf entspricht einer Dilution von über 60%.
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
9 | Precision Bio aufwärts mit neuer WKN | moneywork4me | Balu4u | 04.04.24 19:07 | ||
2 | 125 | Precision Biosciences DL !....Zombie oder.. | Cashback | Vassago | 01.03.24 16:21 |